Compugen: Rises as co gets new patent for cancer treatment in Europe

Compugen

22/04/2020 16:26

** U.S.-listed shares of drug developer  CGEN.O  rise 7.2%
to $14.97 after the European Patent Office grants new patent for
composition of co's experimental cancer treatment COM701 
    ** Patent is expected to expire in Europe in February 2036;
COM701 is currently being tested in an early-stage study
 urn:newsml:reuters.com:*:nPnbHkMKHa
    ** Shares up ~151% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))